Natixis’s Dyne Therapeutics DYN Stock Holding History

Natixis’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,000	Closed	-$397K	–	1042
2024 Q1	$397K	Sell	14,000 -26,000	-65%	-$588K	﹤0.01%	654
2023 Q4	$532K	Buy	+40,000	New	+$391K	﹤0.01%	604

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Natixis's DYN Position: Q2 2024 in Review

Natixis sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 14,000 shares — an estimated $397K sold.

Natixis first reported a position in DYN in Q4 2023 and held it in 2 quarters. The position peaked at $532K in Q4 2023. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

Natixis reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
Natixis sold 14,000 Dyne Therapeutics shares in Q2 2024, an estimated $397K.
Natixis first reported a position in Dyne Therapeutics in Q4 2023 and held it in 2 quarters.
Natixis's Dyne Therapeutics position peaked at $532K in Q4 2023.
193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.